Anavex Life Sciences Corp (AVXL)

[A_Good_Day_2]

None of that matters. Data was spectacular at 12 months. If 15-month data was released the pps would not have moved hardly at all, even if it continued to be spectacular. The trial is not designed to prove efficacy and no serious investor is going to give it more than anecdotal, speculative meaning.

The real value of the 2a results is in dose optimization and safety. That was already proven earlier in the study.

All that is important now is 2/3 starting. Once data from that trial starts being reported (if it is good) we will launch.